Vai al contenuto principale
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Osservazionale500 partecipanti ricercati21 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Patologie

  • Limbal Stem Cell Deficiency

Idoneità

Idoneità
SessoTutti
Età12 Years – 99 Years
Volontari saniNo
Metodo di campionamentoPROBABILITY_SAMPLE

Popolazione dello studio

Adult and adolescent subjects with qualifying LSCD

Idoneità come riportata nel registro

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioOsservazionale
FaseNon indicato nella scheda del registro
AssegnazioneNon indicato nella scheda del registro
Modello di interventoNon indicato nella scheda del registro
Finalità principaleNon indicato nella scheda del registro
MascheramentoNon indicato nella scheda del registro
Arruolamento500 partecipanti ricercati

Sponsor e collaboratori

  • Claris Biotherapeutics, Inc. Sponsor

Bracci e interventi

  • Non-interventional

    No product administration.

Interventi

  • Altro Non-interventional

    Non-interventional

Esiti misurati

  1. Esito primario

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Orizzonte temporale Screening through Week 84

  2. Esito primario

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Orizzonte temporale Screening through Week 84

  3. Esito primario

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Orizzonte temporale Screening through Week 84

  4. Esito primario

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Orizzonte temporale Screening through Week 84

  5. Esito primario

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Orizzonte temporale Screening through Week 84

  6. Esito primario

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Orizzonte temporale Screening through Week 84

  7. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Orizzonte temporale Screening through Week 84

  8. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Orizzonte temporale Screening through Week 84

  9. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Orizzonte temporale Screening through Week 84

  10. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Orizzonte temporale Screening through Week 84

  11. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Orizzonte temporale Screening through Week 84

  12. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Orizzonte temporale Screening through Week 84

  13. Esito secondario

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Orizzonte temporale Screening through Week 84

Date

Date
Data di inizio22 maggio 2026 (effettiva)
Conclusione primaria1 marzo 2028 (stimata)
Conclusione1 marzo 2028 (stimata)
Prima pubblicazione9 giugno 2026 (effettiva)
Ultimo aggiornamento18 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltanovembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

21 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Claris Investigative SiteCarmelIndianaIn reclutamento
Claris Investigative SiteCranberry TownshipPennsylvaniaIn reclutamento
Claris Investigative SiteDraperUtahIn reclutamento
Claris Investigative SiteHuntington BeachCaliforniaIn reclutamento
Claris Investigative SiteIndianapolisIndianaIn reclutamento
Claris Investigative SiteKansas CityMissouriIn reclutamento
Claris Investigative SiteLa JollaCaliforniaIn reclutamento
Claris Investigative SiteLos AngelesCaliforniaIn reclutamento
Claris Investigative SiteLouisvilleKentuckyIn reclutamento
Claris Investigative SiteMinnetonkaMinnesotaIn reclutamento
Claris Investigative SiteNorfolkVirginiaIn reclutamento
Claris Investigative SiteOverland ParkKansasIn reclutamento
Claris Investigative SitePalisades ParkNew JerseyIn reclutamento
Claris Investigative SitePortlandOregonIn reclutamento
Claris Investigative SiteRockville CentreNew YorkIn reclutamento
Claris Investigative SiteSan AntonioTexasIn reclutamento
Claris Investigative SiteSioux FallsSouth DakotaIn reclutamento
Claris Investigative SiteSmyrnaTennesseeIn reclutamento
Claris Investigative SiteSouth DartmouthMassachusettsIn reclutamento
Claris Investigative SiteTampaFloridaIn reclutamento
Claris Investigative SiteWichitaKansasIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 18 novembre 2026

    Centro aggiunto

    13 sites added (21 total)

    821

  2. 6 agosto 2026

    Centro aggiunto

    6 sites added (8 total)

    28